
MUSCLE HEMANGIOMATOSIS PRESENTING AS
A SEVERE FEATURE IN A PATIENT WITH THE PTEN
MUTATION: EXPANDING THE PHENOTYPE OF
VASCULAR MALFORMATIONS IN
BANNAYAN-RILEY-RUVALCABA SYNDROME Soysal Y, Acun T, Lourenço CM, Marques W Jr, Yakıcıer MC *Corresponding Author: Assistant Professor Yasemin Soysal, Department of Medical Genetics, Afyon
Kocatepe University, Faculty of Medicine, Ali Çetinkaya Kampüsü, Afyonkarahisar, 03100, Turkey; Tel.:
+90-5423463576; Fax: +90-2722463300; E-mail: yasemin_soysal@yahoo.com page: 45
|
MATERIALS AND METHODS
Clinical Report. The proband was an 8-yearold
female, referred to the Neurogenetic Division,
University of São Paulo-Clinics Hospital, Ribeirao
Preto, São Paulo, Brazil, because of recurrent facial
palsy. She was the second child of healthy and non
onsanguineous parents. Further family history was
unremarkable. She was born by vaginal delivery
at term; her birth weight, length, and occipitofrontal
circumference (OFC) were not recorded at that
time. Her growth parameters were normal during
childhood. At 2 years of age, she developed recurrent
attacks of facial palsy with full recovery days
after the episode; there were no other similar cases
in her family. Her medical history included one episode
of seizures at 3 years of age, but she did not use
anticonvulsants. At 7 years of age, she developed
gait problems because of pain in her left leg and was
evaluated by an orthopedic surgeon who diagnosed
hemangiomas. The hemangioma was excised. After
histopathological examination, the lesion was diagnosed
as an angiolipoma. However, she had another
hemangioma in the same leg several months later.
At that time her parents noticed that her leg became
thinner. New hemangiomas appeared in her right
leg, but the parents decided not to operate until they
had a defi nite diagnosis. Her teachers noticed learning
disabilities in school. At the age of 8, her weight
and height were in the 50th percentile and her OFC
was greater than the 97th percentile for her age.
Her parents’ OFC were in the normal range. When
she was 10, her left leg was amputated because of
the hemangioma. On phenotypic inspection, a mild
facial dysmorphism consisting of a high forehead,
a triangular face, pointed chin, down-slanting palpebral
fi ssures, and a high-arched palate were observed.
Several verrucae vulgares on her arms and
hands and small café-au-lait spots on her arms and
trunk were identifi ed.
Neurological examination identifi ed a mildly
asymmetric face, normal eye movements, brisk
osteotendinous refl exes, and no signs of cerebellar
ataxia. Interestingly, the patient had facial palsy.
The weakness in her left leg included a moderate
degree of muscle atrophy and aqueous retraction.
Her biochemical and serological tests (including
thyroid function and karyotype) were all normal.
Electroencephalogram (EEG) monitoring recorded
as normal. Electromyography (EMG) revealed the
presence of myopathic potential units, but nerve
conduction velocities were normal. Abdominal
ultrasound monitoring recorded as normal.
Magnetic resonance imaging (MRI) of the brain
showed a small cavitation on the atrium of left lateral
ventricle compatible with increased perivascular
space. An MRI of the lower limbs showed
normal fi ndings in left leg; her right leg displayed
the presence of arteriovenous malformation
of the right buttock thorough the right lower
limbs and severe muscle atrophy. Because of the
combination of macrocephaly, angiomyolipomas,
and myopathy, we hypothesized that she might
have Bannayan-Zonana syndrome, and performed
a thyroid ultrasound and colonoscopy. The
thyroid ultrasound showed no abnormal fi ndings;
colonoscopy showed a few polyps in the sigmoid
colon. The results of biopsy on the polyps were
compatible with hamartomatous type lesions. In
our patient, the existence of hemangiomas, severe
vascular malformation leading to amputation of
an extremity, macrocephaly, dermatologic and
neurologic fi ndings, and facial dysmorphisms in
childhood supported a diagnosis of BRRS and an
evaluation of PTEN mutation analysis. After we
obtained written informed consent from her parents
(Ethical Committee for Medical Research document number 12219/2004), we carried out a direct DNA
sequencing of the whole PTEN gene exons.
Characterization of the PTEN Mutation.
We extracted genomic DNA from peripheral blood
leukocytes by means of a commercial kit (QIAamp
51104; Qiagen, Hilden, Germany). We then
amplifi ed genomic DNA using primers fl anking
the exons of PTEN. Primer sequences and their Tm
values are given in Table 1. Reaction conditions
were as follows: after initial denaturation at 98C
for 1 min., three steps were repeated for 35 cycles
(denaturation for 8 seconds at 98C, annealing for
8 seconds at 60C and extension for 15 seconds
at 72C). The reaction was fi nished with a fi nal
extension for 1 min. at 72C. The polymerase chain
reaction (PCR) products were directly sequenced
by a sequencing service company, Iontek (Istanbul,
Turkey), to detect mutation. We used the Mutation
Surveyor software package (v 3.10, SoftGenetics,
LLC, State College, PA, USA) for mutation
screening.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|